Venture Certified
| 벤처투자유형 | 2024-01-31 ~ 2027-01-30 | 20240131010027 | 2024-01-31 |
Revenue CAGR +75.8%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.2B | 0.3B | 0.1B |
| Operating Profit | -2.3B | -1.2B | -0.3B |
| Net Profit | -2.6B | -1.2B | -0.3B |
| Total Assets | 9.0B | 6.7B | 0.7B |
| Total Liabilities | 12.8B | 8.0B | 0.7B |
| Total Equity | -3.9B | -1.3B | -0.1B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -2B
3 Consecutive Years of Net Loss
▲ 27.2%
▼ 214.2%
▼ 161.7%
▲ 62.1%
▼ 73.7%
| Name | Position | Role |
|---|---|---|
| 홍준만 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "경기도 용인시",
"ceo_name": "홍준만",
"certificate": [
{
"cert_number": "20240131010027",
"changes": "",
"disclosure_date": "2024-01-31",
"first_cert_date": "2024-01-31",
"no": "1",
"type": "벤처투자유형",
"valid_period": "2024-01-31 ~ 2027-01-30"
}
],
"company_name": "(주)알엔에이치바이오",
"corp_no": "131111-*******",
"financials": {
"2022": {
"capital_stock": 20000000,
"cost_of_sales": 2500000,
"current_assets": 66674000,
"current_liabilities": 3110000,
"gross_profit": 4318000,
"net_income": -26436000,
"net_income_bs": -26436000,
"non_current_assets": 0,
"non_current_liabilities": 70000000,
"non_operating_expenses": 361000,
"non_operating_income": 6000,
"operating_profit": -26081000,
"revenue": 6818000,
"sga_expenses": 30399000,
"total_assets": 66674000,
"total_equity": -6436000,
"total_liabilities": 73110000
},
"2023": {
"capital_stock": 20000000,
"cost_of_sales": 8365000,
"current_assets": 157243000,
"current_liabilities": 5561000,
"gross_profit": 17958000,
"net_income": -122735000,
"net_income_bs": -122735000,
"non_current_assets": 509147000,
"non_current_liabilities": 790000000,
"non_operating_expenses": 4982000,
"non_operating_income": 5651000,
"operating_profit": -123404000,
"revenue": 26323000,
"sga_expenses": 141362000,
"total_assets": 666390000,
"total_equity": -129171000,
"total_liabilities": 795561000
},
"2024": {
"capital_stock": 20000000,
"cost_of_sales": 5839000,
"current_assets": 341787000,
"current_liabilities": 12089000,
"gross_profit": 15243000,
"net_income": -256976000,
"net_income_bs": -256976000,
"non_current_assets": 554155000,
"non_current_liabilities": 1270000000,
"non_operating_expenses": 29428000,
"non_operating_income": 7320000,
"operating_profit": -234868000,
"revenue": 21082000,
"sga_expenses": 250111000,
"total_assets": 895942000,
"total_equity": -386147000,
"total_liabilities": 1282089000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "300,000,000",
"changes": "300,000,000",
"date": "2023-07-12"
}
],
"main_products": "엑소좀",
"phone": "031-895-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |